Estimation of Seasonal Influenza Vaccine Effectiveness Using Data Collected in Primary Care in France: Comparison of the Test-negative Design and the Screening Method
Overview
Authors
Affiliations
Objectives: We discussed which method between the test-negative design (TND) and the screening method (SM) could provide more robust real-time and end-of-season vaccine effectiveness (VE) estimates using data collected from routine influenza surveillance in primary care.
Methods: We used data collected during two influenza seasons, 2014-15 and 2015-16. Using the SM, we estimated end-of-season VE in preventing medically attended influenza-like illness and laboratory-confirmed influenza among the population at risk. Using the TND, we estimated end-of-season VE in preventing influenza among both the general and the at-risk population. We estimated real-time VE using both methods.
Results: For the SM, the overall adjusted end-of-season VE was 24% (95% confidence interval (CI), 16 to 32) and 12% (95% CI, -16 to 33) during season 2014-15, and 53% (95% CI, 44 to 60) and 47% (95% CI, 23 to 64) during season 2015-16, in preventing influenza-like illness and laboratory-confirmed influenza, respectively. For the TND, the overall adjusted end-of-season VE was -17% (95% CI, -79 to 24) and -38% (95% CI, -199 to 13) in 2014-15, and 10% (95% CI, -31 to 39) and 18% (95% CI, -33 to 50) in 2015-16, among the general and at-risk population, respectively. Real-time VE estimates obtained through the TND showed more variability across each season and lower precision than those estimated with the SM.
Conclusions: Although the worldwide use of the TND allows for comparison of overall VE estimates among countries, the SM performs better in providing robust real-time VE estimates among the population at risk.
Common communicable diseases in the general population in France during the COVID-19 pandemic.
Launay T, Souty C, Vilcu A, Turbelin C, Blanchon T, Guerrisi C PLoS One. 2021; 16(10):e0258391.
PMID: 34634090 PMC: 8504745. DOI: 10.1371/journal.pone.0258391.
Okoli G, Racovitan F, Abdulwahid T, Hyder S, Lansbury L, Righolt C Open Forum Infect Dis. 2021; 8(3):ofab069.
PMID: 33738320 PMC: 7953658. DOI: 10.1093/ofid/ofab069.
Chua H, Feng S, Lewnard J, Sullivan S, Blyth C, Lipsitch M Epidemiology. 2019; 31(1):43-64.
PMID: 31609860 PMC: 6888869. DOI: 10.1097/EDE.0000000000001116.
Souty C, Masse S, Valette M, Behillil S, Bonmarin I, Pino C Clin Microbiol Infect. 2019; 25(9):1147-1153.
PMID: 30703528 PMC: 7172742. DOI: 10.1016/j.cmi.2019.01.014.
Souty C, Amoros P, Falchi A, Capai L, Bonmarin I, van der Werf S Influenza Other Respir Viruses. 2018; 13(2):148-157.
PMID: 30428158 PMC: 6379635. DOI: 10.1111/irv.12620.